These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 33630021)

  • 21. Addiction in the family: Two Indigenous families overcoming barriers to opioid agonist therapy.
    Lawford K; Newman A
    Can Fam Physician; 2022 May; 68(5):348-351. PubMed ID: 35552202
    [No Abstract]   [Full Text] [Related]  

  • 22. Enhancing engagement between legislators and nursing to increase buprenorphine access.
    Finnell DS; Schimmels J; Tierney M
    Nurs Outlook; 2023; 71(4):102004. PubMed ID: 37429154
    [No Abstract]   [Full Text] [Related]  

  • 23. Making Amends for the Opioid Epidemic.
    Sharfstein JM; Olsen Y
    JAMA; 2019 Apr; 321(15):1446-1447. PubMed ID: 30990541
    [No Abstract]   [Full Text] [Related]  

  • 24. Methadone and buprenorphine treatments in patients with schizophrenia.
    Dervaux A; Plancke L; Amariei A; Trouiller P; Tahon M; Martinetti MP; Naassila M; Cottencin O; Danel T
    Schizophr Res; 2019 Jul; 209():286-288. PubMed ID: 31101511
    [No Abstract]   [Full Text] [Related]  

  • 25. A Community Partnership to Improve Access to Buprenorphine in a Homeless Population.
    Leo P; Gastala N; Fleurimont J; Messmer S; Maes P; Richardson J; Neeb C; Stackhouse N; Koruba S; Watson DP
    Ann Fam Med; 2021; 19(1):85. PubMed ID: 33431401
    [No Abstract]   [Full Text] [Related]  

  • 26. Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.
    Cottrill CB; Matson SC
    Adolesc Med State Art Rev; 2014 Aug; 25(2):251-65. PubMed ID: 27132312
    [No Abstract]   [Full Text] [Related]  

  • 27. [Should high-dose buprenorphine be withdrawn from the French market?].
    Rolland B; Muyssen A; Danel T; Cottencin O
    Rev Epidemiol Sante Publique; 2013 Apr; 61(2):91-2. PubMed ID: 23489947
    [No Abstract]   [Full Text] [Related]  

  • 28. Commentary on Cousins et al. (2016): Accumulating evidence on risk of mortality on and off opioid substitution treatment.
    Hickman M; Macleod J; Degenhardt L
    Addiction; 2016 Jan; 111(1):83-4. PubMed ID: 26669528
    [No Abstract]   [Full Text] [Related]  

  • 29. Medicines for Patients After an Opioid Overdose.
    Ann Intern Med; 2018 Aug; 169(3):. PubMed ID: 29913484
    [No Abstract]   [Full Text] [Related]  

  • 30. Buprenorphine for prescription opioid addiction in a patient with depression and alcohol dependence.
    Fishman MJ; Wu LT; Woody GE
    Am J Psychiatry; 2011 Jul; 168(7):675-9. PubMed ID: 21724673
    [No Abstract]   [Full Text] [Related]  

  • 31. Medication-Based Treatment to Address Opioid Use Disorder.
    Leshner AI; Dzau VJ
    JAMA; 2019 Jun; 321(21):2071-2072. PubMed ID: 31046072
    [No Abstract]   [Full Text] [Related]  

  • 32. Barriers and facilitators to buprenorphine use for opioid agonist treatment: protocol for a scoping review.
    Leece P; Khorasheh T; Corace K; Strike C; Bayoumi AM; Taha S; Marks E; Pach B; Ahamad K; Grennell E; Holowaty M; Manson H; Straus SE
    BMJ Open; 2019 Dec; 9(12):e032285. PubMed ID: 31843837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Buprenorphine Out-of-Pocket Costs and Discontinuation in Privately Insured Adults With Opioid Use Disorder.
    Leech AA; McNeer E; Roberts AW; Dusetzina SB; Lai P; Morgan JR; Patrick SW
    JAMA Intern Med; 2023 Sep; 183(9):1023-1026. PubMed ID: 37548972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Opioid misuse epidemic: Addressing opioid prescribing and organization initiatives for holistic, safe and compassionate care.
    Naegle M; ; Mitchell AM; ; Flinter M; ; Dunphy L; ; Vanhook P; ; Delaney KR;
    Nurs Outlook; 2017; 65(4):477-479. PubMed ID: 28821312
    [No Abstract]   [Full Text] [Related]  

  • 35. Primary care management of opioid dependence: the addition of CBT gives no extra benefit compared to standard physician management alone.
    Miotto K
    Evid Based Ment Health; 2013 Aug; 16(3):76. PubMed ID: 23616210
    [No Abstract]   [Full Text] [Related]  

  • 36. Time to include buprenorphine-naloxone combination in the WHO Model List of Essential Medicines.
    Balhara YP
    J Opioid Manag; 2013; 9(4):237. PubMed ID: 24380101
    [No Abstract]   [Full Text] [Related]  

  • 37. Opioid dependence - management in general practice.
    Frei M
    Aust Fam Physician; 2010 Aug; 39(8):548-52. PubMed ID: 20877747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Buprenorphine charges to uninsured patients at top-ranked U.S. hospitals.
    Niforatos JD; Dorner SC; Pescatore RM; Raja AS
    Am J Emerg Med; 2019 Dec; 37(12):2253-2254. PubMed ID: 31047741
    [No Abstract]   [Full Text] [Related]  

  • 39. Buprenorphine for Persons on Waiting Lists for Treatment for Opioid Dependence.
    Yan K
    N Engl J Med; 2017 Mar; 376(10):1000. PubMed ID: 28276662
    [No Abstract]   [Full Text] [Related]  

  • 40. Buprenorphine for Persons on Waiting Lists for Treatment for Opioid Dependence.
    Sigmon SC; Schwartz RP; Higgins ST
    N Engl J Med; 2017 Mar; 376(10):1000-1001. PubMed ID: 28273017
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.